Last reviewed · How we verify

Liposomal Bupivacaine 13.3

Pacira Pharmaceuticals, Inc · Phase 1 active Small molecule

Liposomal Bupivacaine 13.3 is a Small molecule drug developed by Pacira Pharmaceuticals, Inc. It is currently in Phase 1 development.

At a glance

Generic nameLiposomal Bupivacaine 13.3
SponsorPacira Pharmaceuticals, Inc
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Liposomal Bupivacaine 13.3

What is Liposomal Bupivacaine 13.3?

Liposomal Bupivacaine 13.3 is a Small molecule drug developed by Pacira Pharmaceuticals, Inc.

Who makes Liposomal Bupivacaine 13.3?

Liposomal Bupivacaine 13.3 is developed by Pacira Pharmaceuticals, Inc (see full Pacira Pharmaceuticals, Inc pipeline at /company/pacira-pharmaceuticals-inc).

What development phase is Liposomal Bupivacaine 13.3 in?

Liposomal Bupivacaine 13.3 is in Phase 1.

Related